Streamline Health Solutions (STRM) 10-Q 14 Sep 23 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jul. 31, 2023	Sep. 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--01-31
Entity File Number	000-28132
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS, INC.
Entity Central Index Key	0001008586
Entity Tax Identification Number	31-1455414
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2400 Old Milton Pkwy.
Entity Address, Address Line Two	Box 1353
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30009
City Area Code	(888)
Local Phone Number	997-8732
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	STRM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		58,895,071

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2023	Jan. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,087,000	$ 6,598,000
Accounts receivable, net of allowance for credit losses of $94,000 and $132,000, respectively	2,790,000	7,719,000
Contract receivables	940,000	960,000
Prepaid and other current assets	895,000	710,000
Total current assets	8,712,000	15,987,000
Non-current assets:
Property and equipment, net of accumulated amortization of $266,000 and $246,000 respectively	106,000	79,000
Right-of use asset for operating lease		32,000
Capitalized software development costs, net of accumulated amortization of $7,107,000 and $6,224,000, respectively	6,105,000	5,846,000
Intangible assets, net of accumulated amortization of $3,527,000 and $2,627,000, respectively	13,893,000	14,793,000
Goodwill	23,089,000	23,089,000
Other	1,410,000	1,695,000
Total non-current assets	44,603,000	45,534,000
Total assets	53,315,000	61,521,000
Current liabilities:
Accounts payable	657,000	626,000
Accrued expenses	1,939,000	3,265,000
Current portion of term loan	1,000,000	750,000
Deferred revenues	6,724,000	8,361,000
Current portion of operating lease obligation		35,000
Acquisition earnout liability	3,015,000	3,738,000
Total current liabilities	13,335,000	16,775,000
Non-current liabilities:
Term loan, net of current portion and deferred financing costs	8,517,000	8,964,000
Deferred revenues, less current portion	212,000	167,000
Other non-current liabilities	147,000	104,000
Total non-current liabilities	8,876,000	9,235,000
Total liabilities	22,211,000	26,010,000
Stockholders’ equity:
Common stock, $0.01 par value per share, 85,000,000 shares authorized; 58,895,071 and 57,567,210 shares issued and outstanding, respectively	589,000	576,000
Additional paid in capital	132,933,000	131,973,000
Accumulated deficit	(102,418,000)	(97,038,000)
Total stockholders’ equity	31,104,000	35,511,000
Total liabilities and stockholders’ equity	$ 53,315,000	$ 61,521,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jul. 31, 2023	Jan. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 94,000	$ 132,000
Accumulated amortization, property and equipment	266,000	246,000
Accumulated amortization, capitalized software development costs	7,107,000	6,224,000
Accumulated amortization, intangible assets	$ 3,527,000	$ 2,627,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	85,000,000	85,000,000
Common stock, shares issued	58,895,071	57,567,210
Common stock, shares outstanding	58,895,071	57,567,210

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Revenues:
Total revenues		$ 5,770,000	$ 5,992,000	$ 11,102,000	$ 11,927,000
Operating expenses:
Cost of software as a service		1,893,000	1,532,000	3,482,000	3,029,000
Cost of maintenance and support		32,000	90,000	121,000	136,000
Cost of professional fees and licenses		1,022,000	1,582,000	2,130,000	3,248,000
Selling, general and administrative expense		4,107,000	3,934,000	7,913,000	8,435,000
Research and development		1,305,000	1,461,000	3,006,000	2,773,000
Acquisition-related costs		9,000	49,000	44,000	139,000
Total operating expenses		8,368,000	8,648,000	16,696,000	17,760,000
Operating loss		(2,598,000)	(2,656,000)	(5,594,000)	(5,833,000)
Other (expense) income:
Interest expense		(267,000)	(189,000)	(515,000)	(321,000)
Acquisition earnout valuation adjustments		359,000	(475,000)	723,000	25,000
Other		(1,000)	50,000	31,000	83,000
Loss before income taxes		(2,507,000)	(3,270,000)	(5,355,000)	(6,046,000)
Income tax expense		(8,000)	(2,000)	(61,000)	(13,000)
Net loss		$ (2,515,000)	$ (3,272,000)	$ (5,416,000)	$ (6,059,000)
Basic and Diluted Earnings Per Share:
Net loss per common share - basic		$ (0.04)	$ (0.07)	$ (0.10)	$ (0.13)
Net loss per common share - diluted		$ (0.04)	$ (0.07)	$ (0.10)	$ (0.13)
Weighted average number of common shares - basic	[1]	56,357,684	47,231,296	56,164,282	47,129,879
Weighted average number of common shares - diluted		56,357,684	47,231,296	56,164,282	47,129,879
Software as a Service [Member]
Revenues:
Total revenues		$ 3,531,000	$ 3,117,000	$ 6,706,000	$ 5,948,000
Maintenance and Support [Member]
Revenues:
Total revenues		1,100,000	1,118,000	2,257,000	2,228,000
Professional Fees and Licenses [Member]
Revenues:
Total revenues		$ 1,139,000	$ 1,757,000	$ 2,139,000	$ 3,751,000
[1]Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2023 and 2022, there were 2,484,071 1,564,031

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jan. 31, 2022	$ 478,000	$ 119,225,000	$ (86,659,000)	$ 34,044,000
Beginning balance, shares at Jan. 31, 2022	47,840,950
Restricted stock issued	$ 4,000	(4,000)
Restricted stock issued, shares	408,031
Restricted stock forfeited
Restricted stock forfeited, shares	(63,900)
Surrender of shares	$ (1,000)	(140,000)		(141,000)
Surrender of shares, shares	(95,701)
Share-based compensation		326,000		326,000
Net loss			(2,787,000)	(2,787,000)
Ending balance, value at Apr. 30, 2022	$ 481,000	119,407,000	(89,446,000)	31,442,000
Ending balance, shares at Apr. 30, 2022	48,089,380
Beginning balance, value at Jan. 31, 2022	$ 478,000	119,225,000	(86,659,000)	34,044,000
Beginning balance, shares at Jan. 31, 2022	47,840,950
Net loss				(6,059,000)
Ending balance, value at Jul. 31, 2022	$ 488,000	119,737,000	(91,718,000)	28,507,000
Ending balance, shares at Jul. 31, 2022	48,801,181
Beginning balance, value at Apr. 30, 2022	$ 481,000	119,407,000	(89,446,000)	31,442,000
Beginning balance, shares at Apr. 30, 2022	48,089,380
Restricted stock issued	$ 7,000	(7,000)
Restricted stock issued, shares	726,801
Restricted stock forfeited
Restricted stock forfeited, shares	(20,000)
Share-based compensation		331,000		331,000
Net loss			(3,272,000)	(3,272,000)
Exercise of Stock Options		6,000		6,000
Exercise of Stock Options, shares	5,000
Ending balance, value at Jul. 31, 2022	$ 488,000	119,737,000	(91,718,000)	28,507,000
Ending balance, shares at Jul. 31, 2022	48,801,181
Beginning balance, value at Jan. 31, 2023	$ 576,000	131,973,000	(97,038,000)	35,511,000
Beginning balance, shares at Jan. 31, 2023	57,567,210
Restricted stock issued	$ 12,000	(12,000)
Restricted stock issued, shares	1,185,927
Restricted stock forfeited	$ (1,000)	1,000
Restricted stock forfeited, shares	(28,400)
Surrender of shares	$ (1,000)	(178,000)		(179,000)
Surrender of shares, shares	(88,326)
Share-based compensation		595,000		595,000
Adoption of ASU 2016-13			36,000	36,000
Net loss			(2,901,000)	(2,901,000)
Ending balance, value at Apr. 30, 2023	$ 586,000	132,379,000	(99,903,000)	33,062,000
Ending balance, shares at Apr. 30, 2023	58,636,411
Beginning balance, value at Jan. 31, 2023	$ 576,000	131,973,000	(97,038,000)	35,511,000
Beginning balance, shares at Jan. 31, 2023	57,567,210
Adoption of ASU 2016-13				36,000
Net loss				(5,416,000)
Ending balance, value at Jul. 31, 2023	$ 589,000	132,933,000	(102,418,000)	31,104,000
Ending balance, shares at Jul. 31, 2023	58,895,071
Beginning balance, value at Apr. 30, 2023	$ 586,000	132,379,000	(99,903,000)	33,062,000
Beginning balance, shares at Apr. 30, 2023	58,636,411
Restricted stock issued	$ 4,000	(4,000)
Restricted stock issued, shares	385,720
Restricted stock forfeited	$ (1,000)	1,000
Restricted stock forfeited, shares	(77,000)
Surrender of shares		(73,000)		(73,000)
Surrender of shares, shares	(50,060)
Share-based compensation		630,000		630,000
Net loss			(2,515,000)	(2,515,000)
Ending balance, value at Jul. 31, 2023	$ 589,000	$ 132,933,000	$ (102,418,000)	$ 31,104,000
Ending balance, shares at Jul. 31, 2023	58,895,071

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Statement of Cash Flows [Abstract]
Net loss	$ (5,416,000)	$ (6,059,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	2,134,000	2,199,000
Acquisition earnout valuation adjustments	(723,000)	(25,000)
Provision for deferred income taxes	43,000
Share-based compensation expense	1,109,000	657,000
Provision for credit losses		21,000
Changes in assets and liabilities:
Accounts and contract receivables	4,985,000	329,000
Other assets	(146,000)	(742,000)
Accounts payable	31,000	(109,000)
Accrued expenses and other liabilities	(1,361,000)	364,000
Deferred revenue	(1,592,000)	414,000
Net cash used in operating activities	(936,000)	(2,951,000)
Cash flows from investing activities:
Purchases of property and equipment	(47,000)	(10,000)
Capitalization of software development costs	(1,026,000)	(871,000)
Net cash used in investing activities	(1,073,000)	(881,000)
Cash flows from financing activities:
Repayment of bank term loan	(250,000)
Payments related to settlement of employee share-based awards	(252,000)	(141,000)
Other		6,000
Net cash used in financing activities	(502,000)	(135,000)
Net decrease in cash and cash equivalents	(2,511,000)	(3,967,000)
Cash and cash equivalents at beginning of period	6,598,000	9,885,000
Cash and cash equivalents at end of period	$ 4,087,000	$ 5,918,000

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay & Benefits, LLC, (collectively, unless the context requires otherwise, “we,” “us,” “our,” “Streamline,” or the “Company”), operate in one segment as a provider of healthcare information technology solutions and associated services. The Company provides these capabilities through the licensing of its Coding & Clinical Documentation Improvement (CDI) solutions, eValuator coding analysis platform, RevID, and other workflow software applications and the use of such applications by software as a service (“SaaS”). The Company also provides audit services to help clients optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare provider information related to the patient revenue cycle. The accompanying unaudited condensed consolidated financial statements have been prepared by us pursuant to the rules and regulations applicable to quarterly reports on Form 10-Q of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. The condensed consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries. In the opinion of the Company’s management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent annual report on Form 10-K. Operating results for the three and six months ended July 31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2024. The Company has one operating segment and one reporting unit due to the singular nature of our products, product development and distribution process, and client base as a provider of computer software-based solutions and services for acute-care healthcare providers. All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar year. Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. To date, the Company has not generated sufficient revenues to allow it to generate free cash flow from operations. The Company has historically accumulated losses and used cash from its financing activities to supplement its operations. Further, the Company’s current forecast projects the Company may not be able to maintain compliance with certain of its financial covenants under its current credit agreement in the future. T In view of these matters, continuation as a going concern is dependent upon the Company’s ability to achieve cash from operations and raise additional debt or equity capital to fund its ongoing operations. The Company expects to achieve positive operating cashflow in the next three fiscal quarters based upon executed contracts which it expects to be fully implemented. This is the first critical step to achieving cash from operations. The Company has approximately $ 9.7 9.0 1.2 1.0 twelve months While the Company is confident in its ability to refinance its existing debt, it does not have written or executed agreements as of the issuance of this Form 10-Q. The Company’s ability to refinance its existing debt is based upon credit markets and economic forces that are outside of its control. The Company believes it has a good working relationship with its current banking partner, Western Alliance Bank, and has seen a positive trend in the credit markets as of late . However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Our significant accounting policies are presented in “Note 2 – Significant Accounting Policies” in the fiscal year 2022 Annual Report on Form 10-K. Users of financial information for interim periods are encouraged to refer to the notes to the consolidated financial statements contained in the Annual Report on Form 10-K when reviewing interim financial results. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates. Fair Value of Financial Instruments The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. There were no transfers of assets or liabilities between Levels 1, 2, or 3 during the six months ended July 31, 2023 and 2022. The table below provides information on the fair value of our liabilities: SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Quoted Prices in Active Markets Significant Other Observable Inputs Significant Value (Level 1) (Level 2) (Level 3) At January 31, 2023 Acquisition earnout liability (1) $ 3,738,000 $ — $ — $ 3,738,000 At July 31, 2023 Acquisition earnout liability (1) $ 3,015,000 $ — $ — $ 3,015,000 (1) The fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the date of acquisition and updated as of July 31, 2023. The change in the fair value of the acquisition earnout liability decreased $ 359,000 723,000 The probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. . A range of possible outcomes is not available under the specific valuation method that was used in determining fair value of the acquisition earnout liability. The significant inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk factors and interest rates. The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan (August 2021) to the date of the most recent balance sheets, July 31, 2023 and January 31, 2023. The term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5 3.25 1.5 0.5 9,301,000 9,550,000 199,000 200,000 Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third-party resellers. Licensed, locally-installed customers on a perpetual model utilize the Company’s support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services and consulting services. We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: SCHEDULE OF DISAGGREGATION OF REVENUE July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Three Months Ended Six Months Ended July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Over time revenue $ 5,770,000 $ 5,940,000 $ 11,028,000 $ 11,804,000 Point in time revenue — 52,000 74,000 5,940,000 Total revenue $ 5,770,000 $ 5,992,000 $ 11,102,000 $ 11,927,000 The Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes (i) software licenses as point in time revenue. Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. The Company’s contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. In the six months ended July 31, 2023, the Company recognized approximately $ 4,815,000 25,352,000 the Company expects to recognize approximately 69% over the next 12 months and the remainder thereafter. Deferred costs (costs to fulfill a contract and contract acquisition costs) The Company defers the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of July 31, 2023 and January 31, 2023, the Company had deferred costs of $ 84,000 94,000 211,000 176,000 17,000 21,000 34,000 40,000 Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one year or less. As of July 31, 2023 and January 31, 2023, deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $ 1,325,000 1,534,000 1,074,000 820,000 125,000 95,000 254,000 186,000 Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three and six months ended July 31, 2023 of $ 537,000 1,109,000 93,000 116,000 331,000 657,000 The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three and six months ended July 31, 2023, the Company issued 0 1,085,000 470,000 800,000 Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. Refer to Note 6 – Income Taxes for further details. The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At July 31, 2023, the Company believes it has appropriately accounted for any uncertain tax positions. Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock. The Company’s unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term. Diluted EPS for the Company’s common stock is computed using the treasury stock method. The following is the calculation of the basic and diluted net loss per share of common stock for the three and six months ended July 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Three Months Ended Six Months Ended July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Basic and diluted loss per share: Net loss $ (2,515,000 ) $ (3,272,000 ) $ (5,416,000 ) $ (6,059,000 ) Basic and diluted net loss per share of common stock from operations $ (0.04 ) $ (0.07 ) $ (0.10 ) $ (0.13 ) Weighted average shares outstanding – Basic (1) 56,357,684 47,231,296 56,164,282 47,129,879 Effect of dilutive securities – Stock options and Restricted stock (2) — — — — Weighted average shares outstanding – Diluted 56,357,684 47,231,296 56,164,282 47,129,879 (1) Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2023 and 2022, there were 2,484,071 1,564,031 (2) Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and six months ended July 31, 2023, diluted earnings per share excludes 618,958 2,484,071 684,125 1,564,031 Other Operating Costs Acquisition-related Costs For the three months and six months ended July 31, 2023, the Company incurred certain acquisition-related costs related to the acquisition of Avelead totaling $ 9,000 44,000 49,000 139,000 Non-Cash Items For the six months ended July 31, 2023, the Company recorded capitalized software purchased with stock, totaling $ 116,000 Accounting Pronouncements Recently Adopted On February 1, 2023, the Company adopted ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 132,000 96,000 36,000 SCHEDULE OF ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2023 Allowance for credit losses $ ( 132,000 ) $ 36,000 — — $ ( 96,000 ) For the period ended July 31, 2023, the Company estimated the current expected credit loss related to accounts receivable using historical credit loss rates and applied an adjustment to account for future economic conditions in accordance with ASU 2016-13. The Company had no further impact on the allowance for credit losses during the six month period ended July 31, 2023. Recent Accounting Pronouncements Not Yet Adopted The Company does not believe there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

BUSINESS COMBINATION

BUSINESS COMBINATION	6 Months Ended
	Jul. 31, 2023
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATION	NOTE 3 — BUSINESS COMBINATION Avelead Acquisition The Company acquired all of the equity interests of Avelead Consulting, LLC (“Avelead”) as part of the Company’s strategic expansion into the acute-care health care revenue cycle management industry (the “Transaction”). The Transaction was completed on August 16, 2021. On November 21, 2022, the Company made cash payments of $ 2,012,000 1,871,037 0.01 5,000,000

OPERATING LEASES

OPERATING LEASES	6 Months Ended
	Jul. 31, 2023
Operating Leases
OPERATING LEASES	NOTE 4 — OPERATING LEASES We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Alpharetta Office Lease On October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia. The sublease term was for 18 292,000 32,000 The Company entered into a lease for office space in Alpharetta, Georgia, on March 1, 2020. The lease terminated on March 31, 2023. At inception, the Company recorded a right-of use asset of $ 540,000 6.5 32,000 97,000 Suwanee Office Lease Upon acquiring Avelead on August 16, 2021 (refer to Note 3 – Business Combination), the Company assumed an operating lease agreement for the corporate office space of Avelead. The lessor is an entity controlled by one of the sellers of Avelead and that seller is a former employee of the Company. The initial 36-month term lease commenced March 1, 2019 and expired on February 28, 2022 6,000

DEBT

DEBT	6 Months Ended
	Jul. 31, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 5 — DEBT Outstanding principal balances consisted of the following at: SCHEDULE OF OUTSTANDING DEBT July 31, 2023 January 31, 2023 Term loan $ 9,500,000 $ 9,750,000 Financing cost payable 104,000 69,000 Deferred financing cost (87,000 ) (105,000 ) Total 9,517,000 9,714,000 Less: Current portion (1,000,000 ) (750,000 ) Non-current portion of debt $ 8,517,000 $ 8,964,000 Term Loan On November 29, 2022, the Company executed a Second Modification to Second Amended and Restated Loan Agreement (the “Second Modification”). The Second Modification includes an expansion of the Company’s total borrowing to include a $ 2,000,000 1.5 3.25 Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial maximum principal amount of $ 10,000,000 1.5 3.25 500,000 1,000,000 2,000,000 3,000,000 The Second Amended and Restated Loan Agreement includes customary financial covenants as follows: ● Minimum Cash Borrowers shall, at all times, maintain unrestricted cash of Borrowers at Bank in an amount not less than Two Million Dollars ($2,000,000). ● Maximum Debt to ARR Ratio SCHEDULE OF MAXIMUM DEBT TO ARR RATIO Quarter Ending Maximum Debt to ARR Ratio October 31, 2022 0.80 1.00 January 31, 2023 0.70 1.00 April 30, 2023 0.65 1.00 July 31, 2023 0.60 1.00 October 31, 2023 0.55 1.00 January 31, 2024 0.50 1.00 ● Maximum Debt to Adjusted EBITDA Ratio SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO Quarter Ending Maximum Debt to Adjusted EBITDA Ratio April 30, 2024 3.50 1.00 July 31, 2024 and on the last day of each quarter thereafter 2.00 1.00 ● Fixed Charge Coverage Ratio 1.20 1.00 The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default. The line of credit also is subject to customary prepayment requirements. Substantially all the assets of the Company are collateralized by the Second Amended and Restated Loan Agreement. For the periods ended January 31, 2023 and July 31, 2023, the Company was in compliance with the Second Amended and Restated Loan Agreement covenants. The Company is forecasted to miss certain future covenants. See Note 1 – Basis of Presentation for detail regarding the Company’s assessment as a going concern. The Company records costs related to the maintenance of the Second Amended and Restated Loan Agreement as deferred financing costs, net of the term loan. These deferred financing costs are being amortized over the remaining term of the loan. The Company has incurred $ 250,000 250,000

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6 — INCOME TAXES Income tax expense increased to $ 61,000 for the six months ended July 31, 2023 compared to $ 13,000 in the prior year comparable period. The effective income tax rate on continuing operations of approximately ( 1 )% differs from our combined federal and state statutory rate of 25 % primarily due to the full valuation allowance the Company currently maintains on its net deferred tax asset. The Company has recorded $ 342,000 333,000 The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2019. All material state and local income tax matters have been concluded for years through January 31, 2018. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2019; however, carryforward losses that were generated prior to the tax year ended January 31, 2019 may still be adjusted by the IRS if they are used in a future period

EQUITY

EQUITY	6 Months Ended
	Jul. 31, 2023
Equity [Abstract]
EQUITY	NOTE 7 — EQUITY Capital Raise On October 24, 2022, the Company entered into purchase agreements with certain investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the “2022 Offering”) an aggregate of 6,299,989 0.01 1.32 8,316,000 Registration of Shares Issued to 180 Consulting On June 22, 2022, the Company filed a Registration Statement on Form S-3 (Registration No. 333-265773) for the purpose of registering for resale 272,653 On June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purpose of registering for resale 394,127 Authorized Shares Increase At the Annual Meeting of Stockholders held on June 7, 2022, the Company’s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan to increase the number of shares of the Company’s common stock authorized for issuance thereunder by 2,000,000 8,223,246 10,223,246 65,000,000 85,000,000 At the Annual Meeting of Stockholders held on June 15, 2023, the Company’s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan to increase the available number of shares of the Company’s common stock authorized for issuance thereunder by 1,000,000 10,223,246 11,223,246

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jul. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 — COMMITMENTS AND CONTINGENCIES Consulting Agreement with 180 Consulting, LLC On March 19, 2020, the Company entered into a Master Services Agreement (the “MSA”) with 180 Consulting, pursuant to which 180 Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among others, through separate executed statements of work (“SOWs”). On September 20, 2021, the Company entered into a separate MSA in support of Avelead products. Certain of the SOWs include the ability of 180 Consulting to earn common stock of the company at a conversion rate to be calculated 20 days after the execution of the related SOW. The MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in this MSA or the related SOWs, individuals providing services to the Company under the MSA and the SOWs may share workspace and administrative costs with 121G Consulting, LLC (“121G”). [Mr. Green is a “member” of 121G, and, accordingly, has a financial interest in that entity.] 180 Consulting earned 131,054 258,153 1,173,357 53,836 109,906 966,000 1,919,000 93,000 116,000 578,000 1,030,000 Inclusive of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense software through 180 Consulting that is owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our clients’ technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180 Consulting licenses the software from 121G at cost. The Company paid approximately $ 264,000 381,000 57,000 140,000

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jul. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 - RELATED PARTY TRANSACTIONS Refer to Note 3 – Business Combination. The Company acquired Avelead on August 16, 2021. Accordingly, the Company assumed a lease for corporate office space from a selling equity-holder of Avelead that is now employed by the Company. This lease term ended February 2023. For the three and six months ended July 31, 2023, the Company recorded rent expense of $ 0 6,000 18,000 37,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jul. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 — SUBSEQUENT EVENTS On September 1, 2023, the Company exercised its right to terminate an employee in accordance with such employee’s employment agreement without cause. In connection with the termination, on September 1, 2023, the Company accelerated the vesting of approximately 150,000 previously outstanding and unvested shares of restricted common stock of the Company (the “Restricted Stock”) held by such employee prior to September 1, 2023. The Company believed it would provide goodwill and future benefit to accelerate the vesting of the 150,000 shares of Restricted Stock for this employee, with fair value totaling approximately $183,000 in stock compensation which will be recognized prospectively and immediately upon vesting, reversing any prior compensation expense recorded. This employee will also forfeit 500,000 options in connection with his termination. The employee is eligible for six months’ severance and certain medical costs due to the termination, totaling approximately $170,000.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. There were no transfers of assets or liabilities between Levels 1, 2, or 3 during the six months ended July 31, 2023 and 2022. The table below provides information on the fair value of our liabilities: SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Quoted Prices in Active Markets Significant Other Observable Inputs Significant Value (Level 1) (Level 2) (Level 3) At January 31, 2023 Acquisition earnout liability (1) $ 3,738,000 $ — $ — $ 3,738,000 At July 31, 2023 Acquisition earnout liability (1) $ 3,015,000 $ — $ — $ 3,015,000 (1) The fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the date of acquisition and updated as of July 31, 2023. The change in the fair value of the acquisition earnout liability decreased $ 359,000 723,000 The probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. . A range of possible outcomes is not available under the specific valuation method that was used in determining fair value of the acquisition earnout liability. The significant inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk factors and interest rates. The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan (August 2021) to the date of the most recent balance sheets, July 31, 2023 and January 31, 2023. The term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5 3.25 1.5 0.5 9,301,000 9,550,000 199,000 200,000
Revenue Recognition	Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third-party resellers. Licensed, locally-installed customers on a perpetual model utilize the Company’s support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services and consulting services. We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: SCHEDULE OF DISAGGREGATION OF REVENUE July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Three Months Ended Six Months Ended July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Over time revenue $ 5,770,000 $ 5,940,000 $ 11,028,000 $ 11,804,000 Point in time revenue — 52,000 74,000 5,940,000 Total revenue $ 5,770,000 $ 5,992,000 $ 11,102,000 $ 11,927,000 The Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes (i) software licenses as point in time revenue. Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. The Company’s contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. In the six months ended July 31, 2023, the Company recognized approximately $ 4,815,000 25,352,000 the Company expects to recognize approximately 69% over the next 12 months and the remainder thereafter. Deferred costs (costs to fulfill a contract and contract acquisition costs) The Company defers the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of July 31, 2023 and January 31, 2023, the Company had deferred costs of $ 84,000 94,000 211,000 176,000 17,000 21,000 34,000 40,000 Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one year or less. As of July 31, 2023 and January 31, 2023, deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $ 1,325,000 1,534,000 1,074,000 820,000 125,000 95,000 254,000 186,000
Equity Awards	Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three and six months ended July 31, 2023 of $ 537,000 1,109,000 93,000 116,000 331,000 657,000 The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three and six months ended July 31, 2023, the Company issued 0 1,085,000 470,000 800,000
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. Refer to Note 6 – Income Taxes for further details. The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At July 31, 2023, the Company believes it has appropriately accounted for any uncertain tax positions.
Net Loss Per Common Share	Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock. The Company’s unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term. Diluted EPS for the Company’s common stock is computed using the treasury stock method. The following is the calculation of the basic and diluted net loss per share of common stock for the three and six months ended July 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Three Months Ended Six Months Ended July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Basic and diluted loss per share: Net loss $ (2,515,000 ) $ (3,272,000 ) $ (5,416,000 ) $ (6,059,000 ) Basic and diluted net loss per share of common stock from operations $ (0.04 ) $ (0.07 ) $ (0.10 ) $ (0.13 ) Weighted average shares outstanding – Basic (1) 56,357,684 47,231,296 56,164,282 47,129,879 Effect of dilutive securities – Stock options and Restricted stock (2) — — — — Weighted average shares outstanding – Diluted 56,357,684 47,231,296 56,164,282 47,129,879 (1) Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2023 and 2022, there were 2,484,071 1,564,031 (2) Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and six months ended July 31, 2023, diluted earnings per share excludes 618,958 2,484,071 684,125 1,564,031
Other Operating Costs	Other Operating Costs Acquisition-related Costs For the three months and six months ended July 31, 2023, the Company incurred certain acquisition-related costs related to the acquisition of Avelead totaling $ 9,000 44,000 49,000 139,000
Non-Cash Items	Non-Cash Items For the six months ended July 31, 2023, the Company recorded capitalized software purchased with stock, totaling $ 116,000
Accounting Pronouncements Recently Adopted	Accounting Pronouncements Recently Adopted On February 1, 2023, the Company adopted ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 132,000 96,000 36,000 SCHEDULE OF ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2023 Allowance for credit losses $ ( 132,000 ) $ 36,000 — — $ ( 96,000 ) For the period ended July 31, 2023, the Company estimated the current expected credit loss related to accounts receivable using historical credit loss rates and applied an adjustment to account for future economic conditions in accordance with ASU 2016-13. The Company had no further impact on the allowance for credit losses during the six month period ended July 31, 2023.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted The Company does not believe there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	The table below provides information on the fair value of our liabilities: SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Quoted Prices in Active Markets Significant Other Observable Inputs Significant Value (Level 1) (Level 2) (Level 3) At January 31, 2023 Acquisition earnout liability (1) $ 3,738,000 $ — $ — $ 3,738,000 At July 31, 2023 Acquisition earnout liability (1) $ 3,015,000 $ — $ — $ 3,015,000 (1) The fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the date of acquisition and updated as of July 31, 2023. The change in the fair value of the acquisition earnout liability decreased $ 359,000 723,000 The probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. . A range of possible outcomes is not available under the specific valuation method that was used in determining fair value of the acquisition earnout liability. The significant inputs include our forecast of Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk factors and interest rates.
SCHEDULE OF DISAGGREGATION OF REVENUE	The following table provides information about disaggregated revenue by type and nature of revenue stream: SCHEDULE OF DISAGGREGATION OF REVENUE July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Three Months Ended Six Months Ended July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Over time revenue $ 5,770,000 $ 5,940,000 $ 11,028,000 $ 11,804,000 Point in time revenue — 52,000 74,000 5,940,000 Total revenue $ 5,770,000 $ 5,992,000 $ 11,102,000 $ 11,927,000
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK	The following is the calculation of the basic and diluted net loss per share of common stock for the three and six months ended July 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Three Months Ended Six Months Ended July 31, 2023 July 31, 2022 July 31, 2023 July 31, 2022 Basic and diluted loss per share: Net loss $ (2,515,000 ) $ (3,272,000 ) $ (5,416,000 ) $ (6,059,000 ) Basic and diluted net loss per share of common stock from operations $ (0.04 ) $ (0.07 ) $ (0.10 ) $ (0.13 ) Weighted average shares outstanding – Basic (1) 56,357,684 47,231,296 56,164,282 47,129,879 Effect of dilutive securities – Stock options and Restricted stock (2) — — — — Weighted average shares outstanding – Diluted 56,357,684 47,231,296 56,164,282 47,129,879 (1) Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2023 and 2022, there were 2,484,071 1,564,031 (2) Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and six months ended July 31, 2023, diluted earnings per share excludes 618,958 2,484,071 684,125 1,564,031
SCHEDULE OF ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED	SCHEDULE OF ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2023 Allowance for credit losses $ ( 132,000 ) $ 36,000 — — $ ( 96,000 )

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jul. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF OUTSTANDING DEBT	Outstanding principal balances consisted of the following at: SCHEDULE OF OUTSTANDING DEBT July 31, 2023 January 31, 2023 Term loan $ 9,500,000 $ 9,750,000 Financing cost payable 104,000 69,000 Deferred financing cost (87,000 ) (105,000 ) Total 9,517,000 9,714,000 Less: Current portion (1,000,000 ) (750,000 ) Non-current portion of debt $ 8,517,000 $ 8,964,000
SCHEDULE OF MAXIMUM DEBT TO ARR RATIO	SCHEDULE OF MAXIMUM DEBT TO ARR RATIO Quarter Ending Maximum Debt to ARR Ratio October 31, 2022 0.80 1.00 January 31, 2023 0.70 1.00 April 30, 2023 0.65 1.00 July 31, 2023 0.60 1.00 October 31, 2023 0.55 1.00 January 31, 2024 0.50 1.00
SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO	SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO Quarter Ending Maximum Debt to Adjusted EBITDA Ratio April 30, 2024 3.50 1.00 July 31, 2024 and on the last day of each quarter thereafter 2.00 1.00

SCHEDULE OF FAIR VALUE ASSETS A

SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)		Jul. 31, 2023	Jan. 31, 2023
Platform Operator, Crypto-Asset [Line Items]
Acquisition earn out liability fair value, observable inputs	[1]	$ 3,015,000	$ 3,738,000
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Acquisition earn out liability fair value, observable inputs	[1]
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Acquisition earn out liability fair value, observable inputs	[1]
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Acquisition earn out liability fair value, observable inputs	[1]	$ 3,015,000	$ 3,738,000
[1]The fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow that was completed at the date of acquisition and updated as of July 31, 2023. The change in the fair value of the acquisition earnout liability decreased $ 359,000 723,000

SCHEDULE OF FAIR VALUE ASSETS_2

SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical) - USD ($)	3 Months Ended	6 Months Ended
	Jul. 31, 2023	Jul. 31, 2023
Accounting Policies [Abstract]
Acquisition earnout liability, change in valuation	$ 359,000	$ 723,000

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) $ in Millions	6 Months Ended
	Jul. 31, 2023 USD ($)
Accounting Policies [Abstract]
Debt, description	The Company has approximately $9.7 million in debt outstanding which represents a debt-to-annual recurring revenue (ARR) ratio of approximately 0.50. The Company believes it has capacity to increase its debt-to-ARR ratio from 0.50 to 1.00 which would add approximately $9.0 million in cash to the Company’s balance sheet. The Company believes a debt-to-ARR ratio of 1.00 is consistent with industry norms
Debt outstanding	$ 9.7
cash	9
Payments of financing costs	1.2
Debt instrument, periodic payment, principal	$ 1
Debt instrument, term	12 months

SCHEDULE OF DISAGGREGATION OF R

SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Product Information [Line Items]
Total revenue	$ 5,770,000	$ 5,992,000	$ 11,102,000	$ 11,927,000
Over Time Revenue [Member]
Product Information [Line Items]
Total revenue	5,770,000	5,940,000	11,028,000	11,804,000
Point in Time Revenue [Member]
Product Information [Line Items]
Total revenue		$ 52,000	$ 74,000	$ 5,940,000

SCHEDULE OF BASIC AND DILUTED N

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) - USD ($)		3 Months Ended				6 Months Ended
		Jul. 31, 2023	Apr. 30, 2023	Jul. 31, 2022	Apr. 30, 2022	Jul. 31, 2023	Jul. 31, 2022
Accounting Policies [Abstract]
Net loss		$ (2,515,000)	$ (2,901,000)	$ (3,272,000)	$ (2,787,000)	$ (5,416,000)	$ (6,059,000)
Basic net loss per share of common stock from operations		$ (0.04)		$ (0.07)		$ (0.10)	$ (0.13)
Diluted net loss per share of common stock from operations		$ (0.04)		$ (0.07)		$ (0.10)	$ (0.13)
Weighted average shares outstanding – Basic	[1]	56,357,684		47,231,296		56,164,282	47,129,879
Effect of dilutive securities – Stock options and Restricted stock	[2]
Weighted average shares outstanding – Diluted		56,357,684		47,231,296		56,164,282	47,129,879
[1]Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2023 and 2022, there were 2,484,071 1,564,031 618,958 2,484,071 684,125 1,564,031

SCHEDULE OF BASIC AND DILUTED_2

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK (Details) (Parenthetical) - shares	3 Months Ended		6 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted earnings per share			2,484,071	1,564,031
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted earnings per share	618,958	684,125	618,958	684,125
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted earnings per share	2,484,071	1,564,031	2,484,071	1,564,031

SCHEDULE OF ACCOUNTING PRONOUNC

SCHEDULE OF ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED (Details) - USD ($)	3 Months Ended	6 Months Ended
	Apr. 30, 2023	Jul. 31, 2023
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 132,000	$ 132,000
Adoption of asu	$ 36,000	36,000
Provision adjustments
Write offs and Recoveries
Allowance for doubtful accounts		$ 96,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended
	Jul. 31, 2023	Apr. 30, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022	Feb. 01, 2023	Jan. 31, 2023
Debt instrument carrying amount	$ 9,500,000			$ 9,500,000			$ 9,750,000
Term loan	9,700,000			9,700,000
Deferred revenue	4,815,000			4,815,000
Revenue remaining performance obligation	25,352,000			$ 25,352,000
Revenue, remaining performance obligation, expected timing of satisfaction, explanation				the Company expects to recognize approximately 69% over the next 12 months and the remainder thereafter.
Deferred costs, net	84,000			$ 84,000			94,000
Accumulated amortization of deferred costs	211,000			211,000			176,000
Deferred costs, amortization expense	17,000		$ 21,000	34,000	$ 40,000
Accumulated amortization	1,074,000			1,074,000			820,000
Compensation expense related to stock-based award				1,109,000	657,000
Acquisition related costs	9,000		$ 49,000	44,000	$ 139,000
Forgiveness of Ppp loan and accrued interest				116,000
Allowance for doubtful accounts	96,000			96,000			132,000
Deferred financing cost	$ 87,000			87,000		$ 96,000	105,000
Adoption of asu		$ 36,000		$ 36,000
Employees [Member]
Restricted common shares	0		470,000	1,085,000	800,000
Equity Award [Member]
Compensation expense related to stock-based award	$ 537,000		$ 331,000	$ 1,109,000	$ 657,000
Equity Award [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Compensation expense related to stock-based award	93,000			116,000
Selling, General and Administrative Expenses [Member]
Deferred sales commissions	125,000		$ 95,000	254,000	$ 186,000
Other Noncurrent Assets [Member]
Deferred commissions costs paid and payable	$ 1,325,000			$ 1,325,000			1,534,000
Second Amended and Restated Loan and Security Agreement [Member]
Variable rate, description				The term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the interest rate spread (the 1.5% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread by analogizing the effect of the change in the published “Corporate Bond Rates,” reduced for any changes in the market interest rate.
Interest rate	1.50%			1.50%
Second Amended and Restated Loan and Security Agreement [Member] | Prime Rate [Member]
Interest rate	3.25%			3.25%
Variable interest rate				1.50%
Debt Agreement [Member]
Interest rate	0.50%			0.50%
Debt instrument carrying amount	$ 9,301,000			$ 9,301,000			9,550,000
Term loan	$ 199,000			$ 199,000			$ 200,000

BUSINESS COMBINATION (Details N

BUSINESS COMBINATION (Details Narrative) - USD ($)	Nov. 21, 2022	Jul. 31, 2023	Jan. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, par value		$ 0.01	$ 0.01
Unit Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to cash acquired	$ 2,012,000
Restricted common stock, shares	1,871,037
Common stock, par value	$ 0.01
Unit Purchase Agreement [Member] | First Year Earnout [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout payment	$ 5,000,000

OPERATING LEASES (Details Narra

OPERATING LEASES (Details Narrative) - USD ($)			3 Months Ended		6 Months Ended
	Oct. 02, 2021	Aug. 16, 2021	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022	Jan. 31, 2023	Oct. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sublease income					$ 32,000
Operating lease, right of use assets							$ 32,000
Lesee discount rate			6.50%		6.50%
Operating lease cost					$ 32,000	$ 97,000
Payments for rent			$ 0	$ 18,000	6,000	$ 37,000
At Inception [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, right of use assets								$ 540,000
Sublease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sublease, term	18 months
Sublease income	$ 292,000
Suwanee Office Lease [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expiration date		Feb. 28, 2022
Payments for rent					$ 6,000

SCHEDULE OF OUTSTANDING DEBT (D

SCHEDULE OF OUTSTANDING DEBT (Details) - USD ($)	Jul. 31, 2023	Feb. 01, 2023	Jan. 31, 2023
Debt Disclosure [Abstract]
Term loan	$ 9,500,000		$ 9,750,000
Financing cost payable	104,000		69,000
Deferred financing cost	(87,000)	$ (96,000)	(105,000)
Total	9,517,000		9,714,000
Less: Current portion	(1,000,000)		(750,000)
Non-current portion of debt	$ 8,517,000		$ 8,964,000

SCHEDULE OF MAXIMUM DEBT TO ARR

SCHEDULE OF MAXIMUM DEBT TO ARR RATIO (Details)	Jul. 31, 2023
October 31, 2022 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	0.80%
October 31, 2022 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	1%
January 31, 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	0.70%
January 31, 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	1%
April 30, 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	0.65%
April 30, 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	1%
July 31, 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	0.60%
July 31, 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	1%
October 31, 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	0.55%
October 31, 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	1%
January 31, 2024 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	0.50%
January 31, 2024 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to ARR Ratio	1%

SCHEDULE OF MAXIMUM DEBT TO ADJ

SCHEDULE OF MAXIMUM DEBT TO ADJUSTED EBITDA RATIO (Details)	Jul. 31, 2023
April 30, 2024 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to Adjusted EBITDA Ratio	3.50%
April 30, 2024 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to Adjusted EBITDA Ratio	1%
July 31, 2024 and Thereafter [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum Debt to Adjusted EBITDA Ratio	2%
July 31, 2024 and Thereafter [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum Debt to Adjusted EBITDA Ratio	1%

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)	Nov. 29, 2022	Aug. 26, 2021	Jul. 31, 2023
Debt Instrument [Line Items]
Principal amount			$ 9,700,000
Second Modification Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 2,000,000
Principal amount	$ 10,000,000
Debt financial covenants, description	Borrowers shall, at all times, maintain unrestricted cash of Borrowers at Bank in an amount not less than Two Million Dollars ($2,000,000).
Second Modification Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Fixed charge coverage ratio			1.20%
Second Modification Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Fixed charge coverage ratio			1%
Second Modification Agreement [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.50%
Debt instrument, interest rate, stated percentage	3.25%
Security Agreement [Member] | Bridge Bank [Member]
Debt Instrument [Line Items]
Long term debt, maturity, year two		$ 500,000
Long term debt, maturity, year three		1,000,000
Long term debt, maturity, year four		2,000,000
Long term debt, maturity, year five		3,000,000
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Amortization of debt issuance costs		250,000
Accretion expense		$ 250,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022	Jan. 31, 2023
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 8,000	$ 2,000	$ 61,000	$ 13,000
Effective Income Tax Rate Reconciliation, Percent			1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			25%
Uncertain tax positions	$ 342,000		$ 342,000		$ 333,000
Income tax description			The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2019. All material state and local income tax matters have been concluded for years through January 31, 2018. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2019; however, carryforward losses that were generated prior to the tax year ended January 31, 2019 may still be adjusted by the IRS if they are used in a future period

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)			6 Months Ended
	Jun. 15, 2023	Oct. 24, 2022	Jul. 31, 2023	Jul. 30, 2023	Jun. 28, 2023	Jan. 31, 2023	Jun. 22, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock par value			$ 0.01			$ 0.01
Number of additional shares authorized to issue	1,000,000		2,000,000
Common stock, shares authorized			85,000,000	65,000,000		85,000,000
180 Consulting LLC [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock issued for resale					394,127		272,653
2013 Incentive Compensation Plan [Member] | Stock Options [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized to issue	10,223,246		8,223,246
2013 Incentive Compensation Plan [Member] | Stock Options [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized to issue	11,223,246		10,223,246
Purchase Agreement [Member]. | 2022 Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued		6,299,989
Common stock par value		$ 0.01
Shares issued, price per share		$ 1.32
Proceeds from issuance of common stock		$ 8,316,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		18 Months Ended
	Jul. 31, 2023	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non employee stock compensation				$ 1,109,000	$ 657,000
Master Services Agreement [Member] | 180 Consulting LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares, issued for services	1,173,357	131,054	53,836	258,153	109,906
Professional fees		$ 966,000	$ 578,000	$ 1,919,000	$ 1,030,000
Master Services Agreement [Member] | 180 Consulting LLC [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non employee stock compensation		93,000		116,000
SOW [Member] | 180 Consulting LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Professional fees		$ 264,000	$ 57,000	$ 381,000		$ 140,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2023	Jul. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Related Party Transactions [Abstract]
Rent expense	$ 0	$ 18,000	$ 6,000	$ 37,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Sep. 01, 2023
Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Share-based compensation arrangement by share-based payment award, terms of award	In connection with the termination, on September 1, 2023, the Company accelerated the vesting of approximately 150,000 previously outstanding and unvested shares of restricted common stock of the Company (the “Restricted Stock”) held by such employee prior to September 1, 2023. The Company believed it would provide goodwill and future benefit to accelerate the vesting of the 150,000 shares of Restricted Stock for this employee, with fair value totaling approximately $183,000 in stock compensation which will be recognized prospectively and immediately upon vesting, reversing any prior compensation expense recorded. This employee will also forfeit 500,000 options in connection with his termination. The employee is eligible for six months’ severance and certain medical costs due to the termination, totaling approximately $170,000.